Intelligent Bio Solutions Azioni (NASDAQ: INBS)

Ultime notizie per Intelligent Bio Solutions (NASDAQ:INBS) Azioni

Intelligent Bio Solutions

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

WIIM

CIVB

Civista Bancshares shares are trading lower after the company announced it will acquire The Farmers Savings Bank and launched a public offering.

News

TKNO

Alpha Teknova Files For Up To $225,000,000 Mixed Shelf

Offerings

KALV

KalVista Pharmaceuticals Entered Into Sales Agreement, Offering Up to $100M Common Stock

Liberty Broadband Corporation ("Liberty Broadband") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>, LBRDK, LBRDP))), announced today that, in connection with its upcoming spin-off (the "Spin-Off") of its wholly owned subsidiary GCI Liberty, Inc. ("GCI Liberty"), it has been advised by Nasdaq that shares of GCI Liberty's Series A common stock and Series C common stock will trade on a when-issued basis on The Nasdaq Global Select Market under the symbols "GLBAV" and "GLBKV", respectively, from July 11, 2025 through July 14, 2025. The Spin-Off is expected to occur after market-close on July 14, 2025 through the distribution, by means of a dividend, of GCI Liberty common stock to holders of record of Liberty Broadband common stock as of 5:00 p.m., New York City time, on June 30, 2025, the record date for the distribution. However, because Nasdaq has established July 15, 2025 as the ex-dividend date for the distribution, and as a result of related "due bill" trading procedures, persons acquiring shares of Liberty Broadband's Series A common stock and Series C common stock in the market through July 14, 2025 will still receive the respective shares of GCI Liberty in the Spin-Off. GCI Liberty Series A common stock and Series C common stock will begin trading in the regular way on Tuesday, July 15, 2025 on The Nasdaq Stock Market under the symbols "GLIBA" and "GLIBK", respectively. GCI Liberty Series B common stock has been approved for quotation on the OTC Markets under the symbol "GLIBB," and quoting is expected to begin on or around Monday, July 21, 2025.

Dividends

LBRDA

LBRDK

LBRDP

Liberty Broadband Spin-Off Of GCI Liberty Set For July 14, 2025; When-Issued Trading Begins July 11, 2025 Under "GLBAV" & "GLBKV", Regular Trading Starts July 15, 2025 On Nasdaq

Janney Montgomery Scott analyst Daniel Cardenas initiates coverage on Burke &amp; Herbert Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHRB#NASDAQ">BHRB</a>) with a Buy rating and announces Price Target of $70.

Price Target

Initiation

Analyst Ratings

BHRB

Janney Montgomery Scott Initiates Coverage On Burke & Herbert Financial with Buy Rating, Announces Price Target of $70

General

RKLB

Rocket Lab Selects Bollinger Shipyards To Support The Build Out Of Rocket Lab's Ocean Landing Platform For Its Neutron Reusable Rocket

Ryder Increases Quarterly Cash Dividend From $0.81 To $0.91

Management

Toll Brothers Appoints Gregg Ziegler To Succeed Marty Connor As CFO

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 5 years by 2.21% on an annualized basis producing an average annual return of 16.64%. Currently, Travelers Companies has a market capitalization of $58.00 billion. 
Buying $1000 In TRV: If an investor had bought $1000 of TRV stock 5 years ago, it would be worth $2,240.81 today based on a price of $255.99 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752179434_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Travelers Companies 5 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 25.26% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 21.34% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 14.58% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 12.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 12.03% at $0.35</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 8.82% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 8.31% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 6.80% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 3.84% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.34% at $0.34</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 3.20% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.05% at $0.10</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 33.50% at $1.35</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 14.29% at $0.0006</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 14.29% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 14.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 12.20% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 6.65% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 5.43% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.05% at $0.64</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 4.93% at $3.06</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 4.79% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 3.10% at $0.25</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLGVF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

FFNTF

GBHPF

GNLN

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MRMD

NWVCF

OILFF

RSSFF

SOLCF

TGIFF

TLRY

UGRO

Cannabis Stock Movers For July 10, 2025

Guidance

LEVI

During Conference Call, Levi Strauss CFO Reportedly Says Co Has Brought 60% Of Inventory Needed To Get Through Second Half Of The Year

Canaccord Genuity analyst Brian McNamara maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and raises the price target from $24 to $25.

EZPW

Canaccord Genuity Maintains Buy on EZCORP, Raises Price Target to $25

NVVE

Nuvve Holding shares are trading lower after the company announced a proposed public offering.

Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) (the "Company" or "Nuvve"), a global leader in vehicle-to-grid (V2G) technology and grid modernization, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Lucid Capital Markets is acting as the sole book-running manager for the offering.

Nuvve Holding Corp. Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed

EQT Corp Expects $720M Gain On Derivatives For Q2 2025

Geo Group Extends Executive Chairman  George C. Zoley's Employment Term From June 30, 2026, To April 2, 2029

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
&nbsp;
SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in animal models—and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs
&nbsp;
On July 10, 2025, MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1)-related anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, setting it apart from earlier CB1-targeting drugs that were discontinued due to serious central nervous system (CNS) effects.
&nbsp;
The study was conducted using the light-dark preference test in zebrafish—a behavioral model used to assess anxiety-related responses. Zebrafish naturally prefer darker environments, but when anxiety levels are elevated, they avoid light even more strongly. Reduced dark preference (i.e., more time spent in the light) is interpreted as a calming effect.
&nbsp;
Four groups were evaluated:
&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Control Group (No Drug): Fish displayed balanced light-dark behavior.</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>CP55,940 Group (CB1 Agonist): At high doses, CP55,940 increased time spent in the dark, indicating anxiety-related behavior. At low doses, it produced a calming effect.</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>Rimonabant Group (CB1 Inverse Agonist): Increased anxiety-like behavior was observed at both high and low doses of CP55,940. The response was greater than that of the CP55,940 group alone, consistent with previously documented psychiatric effects.</td>
</tr>
<tr>
<td>&nbsp;</td>
<td>●</td>
<td>SKNY-1 Groups: In animals co-treated with CP55,940, SKNY-1 reversed the anxiety-inducing effects of high-dose CP55,940 and enhanced the calming effects at low doses. In all treatment conditions, SKNY-1 normalized behavior to control or better-than-control levels.</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;
SKNY-1 is under investigation for its differentiated pharmacological profile, which includes biased CB1 antagonism (blocking β-arrestin signaling while preserving G-protein signaling), partial CB2 receptor activation, mild MAO-B inhibition, and no inhibition of MAO-A as confirmed through in vitro screening. This profile is intended to avoid the psychiatric side effects historically observed with first-generation CB1 antagonists such as rimonabant.
&nbsp;
MIRA Pharmaceuticals, Inc. is currently preparing for shareholder approval in connection with the proposed acquisition of SKNY Pharmaceuticals, Inc. Pending approval, the Company expects to initiate Investigational New Drug (IND)-enabling studies for SKNY-1.

Biotech

MIRA

MIRA Pharmaceuticals Announces New Preclinical Results From SKNY-1, An Oral Drug Candidate For Obesity And Nicotine Addiction Currently Under Definitive Agreement For Acquisition; Reports Clear Reversal Of Anxiety-Related Behavior In Animal Model

Barclays analyst Brandon Oglenski maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Overweight and raises the price target from $135 to $145.

Barclays Maintains Overweight on XPO, Raises Price Target to $145

Civista Bancshares Launches Public Offering

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Equal-Weight and raises the price target from $37 to $39.

Barclays Maintains Equal-Weight on Valaris, Raises Price Target to $39

Press Releases

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion

Earnings

Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

Health Care

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing

Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Harry Simeonidis, President and CEO of Intelligent Bio Solutions Inc.

Contracts

Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion

Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo

Comments

Intelligent Bio Solutions

Notizie

Ultime notizie per Intelligent Bio Solutions (NASDAQ:INBS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO